Imugene Ltd's (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong caught up with Proactive's Andrew Scott to discuss new data given during presentations on the HER-Vaxx cancer immunotherapy program as well as the CF33 oncolytic virus program during the prestigious American Association for Cancer Research (AACR) 2021 Annual Meeting which was held over the weekend. Chong also updates following news the Cohort Review Committee (CRC) has confirmed that the Phase I clinical trial of its checkpoint immunotherapy candidate, PD1-Vaxx, will proceed to the third and final highest dose cohort.
Imugene says 2021 has been 'stellar year so far' as it rapidly advances anti-cancer programs
